	US 12,473,547 B2
	Use of mesenchymal lineage precursor cells or stem cells (MLPSCs) for delivery of oligonucleotides in the treatment of cancer
Peter Brink, New York, NY (US); Ira Cohen, New York, NY (US); Richard Lin, New York, NY (US); Sergey Doronin, New York, NY (US); Irina Potapova, New York, NY (US); Virginijus Valiunas, New York, NY (US); Dan Devine, New York, NY (US); Anthony Sandrasagra, New York, NY (US); Nick Loizos, New York, NY (US); and Silviu Itescu, Melbourne (AU)
Assigned to Mesoblast International Sàrl, Meyrin (SE)
Appl. No. 16/766,206
Filed by Mesoblast International Sárl, Meyrin (CH)
PCT Filed Nov. 21, 2018, PCT No. PCT/IB2018/001439 § 371(c)(1), (2) Date May 21, 2020, PCT Pub. No. WO2019/102268, PCT Pub. Date May 31, 2019.
Claims priority of provisional application 62/589,764, filed on Nov. 22, 2017.
Prior Publication US 2021/0163932 A1, Jun. 3, 2021
Int. Cl. C12N 15/113 (2010.01); A61K 35/28 (2015.01); A61K 38/45 (2006.01); A61P 35/00 (2006.01)

CPC C12N 15/113 (2013.01) [A61K 35/28 (2013.01); A61K 38/45 (2013.01); A61P 35/00 (2018.01); C12Y 204/01214 (2013.01); C12N 2310/11 (2013.01); C12N 2310/141 (2013.01); C12N 2320/32 (2013.01)]

10 Claims

1. A method of treating a cancer in a subject, the method comprising administering to the subject a composition comprising mesenchymal precursor cells (MPCs) or mesenchymal stem cells (MSCs), wherein said MPCs or MSCs comprise an siRNA to KRAS G12D and contact target cancer cells in the subject, whereby the MPCs or MSCs form gap junctions with the contacted target cancer cells, and wherein said cancer comprises an oncogenic G12D mutation in KRAS.